45% keep weight off a year after stopping GLP-1 drugs, study finds

• An actual-world research adopted people who began GLP-1 drugs and discontinued them inside 3 to 12 months to evaluate weight adjustments after stopping therapy.
• Earlier than stopping the drugs, individuals handled for weight problems misplaced about 8.4% of their physique weight, whereas these handled for sort 2 diabetes misplaced about 4.4% on common.
• One 12 months after discontinuation, common weight regain was small. Individuals within the weight problems group regained about 0.5%, whereas these within the diabetes group misplaced a further 1.3% on common, although particular person outcomes different.
• Many individuals continued different types of therapy after stopping GLP-1 medication, which can assist clarify why massive weight regain was not generally noticed.

Two extensively prescribed examples embody semaglutide and tirzepatide. Each have gained world consideration for his or her potential to doubtlessly assist substantial weight reduction. Nevertheless, various factors, reminiscent of doable unwanted effects and prices, could result in discontinuation of those medication.

Thus, questions stay about what occurs when people cease taking these drugs. Some analysis suggests that cessation is usually adopted by fast weight regain and reversal of helpful well being results.

Nevertheless, a brand new research, printed in Diabetes, Obesity and Metabolism, signifies that individuals could preserve a lot of their weight reduction after discontinuation, significantly in the event that they transition to different therapies or life-style assist.

Within the new retrospective cohort research, researchers from the Cleveland Clinic analyzed digital well being document knowledge from 7,938 adults with obese or weight problems who started injectable semaglutide or tirzepatide between 2021 and 2023.

Individuals within the research discontinued therapy inside 3 to 12 months, and researchers tracked their weight adjustments and subsequent therapies for one 12 months after stopping the remedy.

The research crew in contrast weight adjustments amongst individuals who had used the medication for weight problems versus these taking them for sort 2 diabetes.

Earlier than discontinuing therapy, people treating weight problems misplaced a mean of 8.4% of physique weight, whereas these treating sort 2 diabetes misplaced a mean of 4.4% of physique weight.

After 1 12 months with out the remedy, these within the weight problems group regained a mean of 0.5% of physique weight, and people within the diabetes group misplaced a further 1.3% of physique weight on common.

Nevertheless, particular person outcomes different. Within the weight problems group, 55% gained some weight, whereas 45% maintained or continued reducing weight. Within the diabetes group, 44% gained weight and 56% maintained or misplaced weight.

Total, these outcomes recommend that many individuals could not expertise the massive weight regain reported in some randomized medical trials.

Lead research writer, Hamlet Gasoyan, DS, PhD, MPH, a researcher with Cleveland Clinic’s Heart for Worth-Based mostly Care Analysis, spoke to Medical Information At this time, emphasizing the significance of those ends in a real-world setting:

“Randomized medical trials documented that discontinuation of novel weight problems drugs typically leads sufferers to regain weight,” Gasoyan informed us. “For instance, within the SURMOUNT-4 trial, tirzepatide ‘discontinuers’ have been randomized to a placebo, and so they have been unaware whether or not they have been receiving tirzepatide or not.”

“In real-world settings, the commonest causes for discontinuation are price or insurance-related points, and unwanted effects, with the previous predominating,” he added.

“That is why you will need to perceive what further weight administration efforts sufferers pursue in real-world settings after discontinuing semaglutide or tirzepatide, and whether or not long-term weight adjustments after discontinuation comply with the patterns reported in randomized medical trials.”

– Hamlet Gasoyan, DS, PhD, MPH

In line with the researchers, a possible purpose for the distinction could also be that individuals usually proceed their therapy journey in different methods. Inside a 12 months of stopping their unique remedy:

• 27% switched to a different weight problems remedy
• 20% restarted their unique drug
• 14% continued therapy by life-style interventions, reminiscent of visits with dietitians or train specialists
• fewer than 1% underwent bariatric surgical procedure.

These therapy changes could present an evidence for why weight regain appeared smaller than beforehand reported in medical trials.

Gasoyan added that, “on this massive observational research of sufferers who discontinued semaglutide or tirzepatide, reinitiation of the unique remedy or receipt of different weight problems therapy was frequent, which can clarify why they regained much less weight than sufferers in randomized trials.”

Moreover, earlier analysis means that GLP-1 drug discontinuation usually happens for sensible causes slightly than lack of effectiveness.

For instance, insurance coverage protection might also affect therapy patterns. Individuals utilizing the drugs for diabetes have been extra prone to restart remedy than these taking them for weight problems. That is possible as a result of diabetes prescriptions are extra constantly coated by insurance coverage.

The outcomes of this research possible spotlight the significance of ongoing, individualized assist for individuals managing weight problems and sort 2 diabetes.

Whereas rebound weight gain can happen after discontinuing GLP-1 drugs, individuals could proceed to pursue different methods to assist them preserve weight reduction, reminiscent of switching therapies or intensifying life-style adjustments.

Gasoyan expressed hope that this may assist promote conversations between clinicians and people:

“For sufferers who must cease their GLP-1 RA or twin receptor agonist remedy, there are a number of various weight problems therapies accessible. They might need to talk about the accessible choices with their clinician.”

Future analysis could deal with evaluating the effectiveness of various therapies after GLP-1 discontinuation. This might present tips to assist clinicians and people make knowledgeable selections about long-term weight administration.

Commenting on future analysis, Gasoyan informed MNT that “future research ought to look at the comparative effectiveness of therapies for weight problems in sufferers who discontinue their novel GLP-1 RA or twin receptor agonist remedy.”

“We’re already engaged on the following research, the place we look at the comparative effectiveness of different therapy choices for weight problems in sufferers who discontinue semaglutide or tirzepatide, to assist sufferers and their clinicians make knowledgeable selections. This could inform patient-clinician conversations about various choices,” he mentioned.